Luis Jodar

Summary

Publications

  1. ncbi request reprint Development of vaccines against meningococcal disease
    Luis Jodar
    Vaccine Development and Quality and Safety of Biologicals, World Health Organization, Geneva, Switzerland
    Lancet 359:1499-508. 2002
  2. ncbi request reprint Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  3. ncbi request reprint Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants
    Luis Jodar
    Department of Vaccines and Biologicals, World Health Organization, CH 1211 27, Geneva, Switzerland
    Vaccine 21:3265-72. 2003
  4. ncbi request reprint Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines
    Luis Jodar
    World Health Organisation, Geneva, Switzerland
    Vaccine 22:1047-53. 2004

Detail Information

Publications4

  1. ncbi request reprint Development of vaccines against meningococcal disease
    Luis Jodar
    Vaccine Development and Quality and Safety of Biologicals, World Health Organization, Geneva, Switzerland
    Lancet 359:1499-508. 2002
    ..Therefore, there are many promising new vaccine candidates, and improved prospects for development of a broadly protective vaccine for group B disease, and for control of all meningococcal disease...
  2. ncbi request reprint Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries
    Luis Jodar
    WHO, Geneva, Switzerland
    Lancet 361:1902-4. 2003
  3. ncbi request reprint Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants
    Luis Jodar
    Department of Vaccines and Biologicals, World Health Organization, CH 1211 27, Geneva, Switzerland
    Vaccine 21:3265-72. 2003
    ..More detailed recommendations for production and control of pneumococcal conjugate vaccines, including criteria for evaluation for licensure, are currently being drafted...
  4. ncbi request reprint Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines
    Luis Jodar
    World Health Organisation, Geneva, Switzerland
    Vaccine 22:1047-53. 2004
    ..Such vaccines have been shown to offer protective immunity following the introduction of group C conjugates in the UK. The World Health Organisation has produced recommendations for the production and control of these new vaccines...